Skip to main content
Equibles
AGIO logo

AGIO · Agios Pharmaceuticals, Inc. · Metrics

Track AGIO — free

Use AGIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$38.03 +1.18 (+3.20%) At close · Oct 27 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$2.27B
Shares
59.70M
Volume · Oct 27 739.1K Avg daily vol (3M) 1.09M

AGIO metrics

87 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$38.03
Market cap
$2.27B

Price action

20 metrics
Price change (1W)
+3.8%
Price change (30D)
+13.8%
Price change (3M)
+5.7%
Price change (6M)
+53.3%
Price change (YTD)
+39.7%
Price change (1Y)
-11.7%
Trailing year
Price change (5Y)
-19.1%
52-week high
$45.49
52-week low
$22.34
Change from 52-week high
-16.4%
Change from 52-week low
+70.2%
Annualized volatility
77.3%
Annualized volatility (3M)
46.2%
Beta
0.5
RSI (14D)
69.3
Price vs SMA 50
+13.3%
Price vs SMA 200
+20.4%
Avg volume (3M)
1.09M
Relative volume
0.7
Average dollar volume
$36.35M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
59.70M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
22.1×
reciprocal yield 4.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
23.1×
reciprocal yield 4.3%
P / book
2.2
reciprocal yield 45.2%
FCF yield
-16.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
50.0×
reciprocal yield 2.0%
EV / revenue historical average (5Y)
48.5×
reciprocal yield 2.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
92.0%
Operating margin
-466.8%
Trailing 12 months
Net margin
-418.2%
Gross profit (TTM)
$90.47M
Operating profit (TTM)
−$459.02M
Net income (TTM)
−$411.29M
Trailing 12 months
Diluted EPS (TTM)
$-7.02
FCF margin
-371.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.67
Gross profit per diluted share (TTM)
$1.53
Operating profit per diluted share (TTM)
$-7.82
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-7.01
Operating cash flow per diluted share (TTM)
$-6.15
Free cash flow per diluted share (TTM)
$-6.23
Capital expenditures per diluted share (TTM)
$0.08
R&D per diluted share (TTM)
$6.08
Stock compensation per diluted share (TTM)
$0.99
Book value per share
$20.41

Growth

11 metrics
Revenue growth YoY
+259.3%
Year over year
Net income growth YoY
-161.3%
Revenue (TTM)
$98.34M
Trailing 12 months
EPS growth YoY
-161.2%
Shares change YoY
+2.7%
Year over year · more shares
Revenue CAGR (3Y)
+56.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-40.1%
Return on assets
-37.1%
Debt / equity
0.0
Current ratio
10.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$365.25M
Quick ratio
9.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$99.65M
Latest balance sheet
Cash & equivalents
$99.65M
Total assets
$1.11B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$360.60M
Capital expenditures (TTM)
$4.66M
R&D (TTM)
$356.75M
SG&A (TTM)
$192.74M
Stock compensation (TTM)
$57.98M
R&D / revenue
362.8%
Stock compensation / revenue
59.0%

Ownership (13F)

9 metrics
13F filers
239
13F filer change QoQ
+2
Institutional ownership
117.0%
Conviction holders (share of 13F filers)
2.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.0%
Holder tenure
14.1
Price vs estimated holder cost
+16.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
21.7%

Short interest

3 metrics
Short interest
11.5%
Latest settlement · 5.6 days to cover
Days to cover
5.6d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$989,042
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1439222 CUSIP 00847X104 13F (30d) 35 filings 35 filers Visit website Investor relations